Date: 2014-10-09
Type of information: Licensing agreement
Compound: primer extension based target enrichment (PETE) technology
Company: Roche (Switzerland) AbVitro (USA - CA)
Therapeutic area: Technology - Services
Type agreement: licensing
Action mechanism:
Disease:
Details: * On October 9, 2014, Roche announced it made a technology acquisition from AbVitro Inc, a company focused on therapeutic target discovery. Roche obtained exclusive rights to a primer extension based target enrichment technology and associated patent applications filed by AbVitro. Under the terms of the agreement, AbVitro and Roche scientists will collaborate on the development and application of the technology. The primer extension based target enrichment (PETE) technology will be used to support next-generation sequencing directly from blood or other biological samples, a key advantage for clinical sequencing applications. This PETE technology, will be incorporated into Roche’s Sequencing Unit R&D pipeline to support the strategy of providing a full next-generation sequencing workflow solution for clinical sequencing.
Financial terms: Financial terms of the collaboration were not disclosed.
Latest news:
